Histopathologic Damages

The outbreak of the novel coronavirus (SARS-CoV-2) has led to the ongoing pandemic of coronavirus disease (COVID-19). This acute respiratory illness primarily affects the lungs and can result in severe complications leading to the death of the patient. The virus has been found to cause significant histopathological damage in the lungs, which can be observed through a biopsy examination. Histopathological studies have demonstrated that COVID-19 can lead to severe acute respiratory syndrome with diffuse alveolar damage. This damage is characterized by the presence of interstitial edema, inflammatory exudates, hyaline membranes, and alveolar epithelial hyperplasia. The virus can also cause broncho-interstitial pneumonia in which the bronchioles and the alveoli become inflamed and infiltrated by inflammatory cells. Moreover, COVID-19 can lead to vascular damage in which the virus injures the endothelial cells of the blood vessels, leading to the formation of microthrombi. The microthrombi formation can cause pulmonary infarction and exacerbate pre-existing conditions such as hypertension, diabetes mellitus, or heart disease. In addition to the lungs, COVID-19 can affect other organs such as the liver, heart, kidneys, and brain. The histopathological findings in these organs are still under investigation. In summary, COVID-19 can cause severe histopathological damage in the lungs, leading to acute respiratory distress syndrome and broncho-interstitial pneumonia. Moreover, the virus can cause vascular damage, leading to the formation of microthrombi, which can exacerbate pre-existing conditions. The histopathological findings in other organs are still being studied.